National Cancer Institute - Cancer.gov

Juanjuan Ivy Yin, Ph.D.

Ivy Yin, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Senior Research Assistant
Genitourinary Malignancies Branch

RESEARCH SUMMARY

My research interests are focused on 1) the biology of prostate cancer bone metastasis, and 2) the treatment of metastatic castration resistant prostate cancer. 

My research projects are carried out using clinically relevant mouse metastasis models of prostate cancer developed with LuCap-PDXs. Four (4) metastasis models have been developed with three (3) androgen receptor positive adenocarcinoma LuCap-PDX lines, and one AR negative neuroendocrine LuCap-PDX line. The AR positive LuCap-PDX lines predominantly metastasize to bone, and result in osteolytic, osteoblastic, and mixed bone metastases respectively. The AR negative LuCap-PDX line mainly metastasizes to the brain and the spinal cord.

My current work has been devoted to the pathological and molecular characterization of these models using IHC and scRNAseq. In addition, these models have been used to understand the mechanism of castration resistance and to discover effective therapeutics targeting mCRPC. 

Areas of Expertise

Mouse Metastasis Model
Mouse Preclinical Trial For Anti-metastasis Therapies
Live Animal Imaging
Metastatic Bone Disease

Publications

Selected Recent Publications

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence

Fang L, Li D, Yin J, Pan H, Ye H, Bowman J, Capaldo B, Kelly K
Cancer Gene Ther. . Apr 7: 10.1038/s41417-022-00454-5, 2022. [ Journal Article ]

EGR1 regulates angiogenic and osteoclastogenic factors in prostate cancer and promotes metastasis

Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, Beshiri ML, Fang L, Lake RG, Agarwal S, Alilin AN, Xu W, Yin J, Kelly K.
Oncogene. 38(35): 6241-6255, 2019. [ Journal Article ]

High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer

Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, McKnight C, Klummp-Thomas C, Zhang X, Guha R, Hoover S, Simpson RM, Nguyen HM, Corey E, Thomas CJ, Proia DA, Kelly K.
Sci Rep. 8(1): 17239, 2018. [ Journal Article ]

Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration

Ward Y, Lake R, Faraji F, Sperger J, Martin P, Gilliard C, Ku KP, Rodems T, Niles D, Tillman H, Yin J, Hunter K, Sowalsky AG, Lang J, Kelly K
Cell Rep. Apr 17;23(3): 808-822, 2018. [ Journal Article ]

A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening

Beshiri ML, Tice CM, Tran C, Nguyen HM, Sowalsky AG, Agarwal S, Jansson KH, Yang Q, McGowen KM, Yin J, Alilin AN, Karzai FH, Dahut WL, Corey E, Kelly K.
Clin Cancer Res. 24(17): 4332-4345, 2018. [ Journal Article ]